Skip to main content

PUMA BIOTECHNOLOGY INC

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

PBYI$8.14-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

Power of Attorney

KNOWN BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alan H. Auerbach and Maximo Nougues, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and any documents related to this report and filed pursuant to the Securities Exchange Act of 1934, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureDate
/s/ Alan H. AuerbachFebruary 27, 2025
Alan H. Auerbach
(Principal Executive Officer)
/s/ Maximo NouguesFebruary 27, 2025
Maximo Nougues
(Principal Financial Officer and Principal Accounting Officer)
/s/ Alessandra CesanoFebruary 27, 2025
Alessandra Cesano
/s/ Allison DorvalFebruary 27, 2025
Allison Dorval
/s/ Michael P. MillerFebruary 27, 2025
Michael P. Miller
/s/ Jay M. MoyesFebruary 27, 2025
Jay M. Moyes
/s/ Adrian M. SenderowiczFebruary 27, 2025
Adrian M. Senderowicz
/s/ Brian M. StuglikFebruary 27, 2025
Brian M. Stuglik
/s/ Troy E. WilsonFebruary 27, 2025
Troy E. Wilson
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.